APSC2015-1220 Budget Impact of Ticagrelor as Compared to Older Oral Anti-Platelet Drugs: An Indian Perspective

Ticagrelor is a P2Y12 inhibitor indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS). In PLATO study, Ticagrelor has shown to reduce the rate of a combined endpoint of CV death, MI or stroke, rate of stent thrombosis compared to clopidogrel. As of Clopidogrel, the price of Ticagrelor is higher, but the benefits derived are significant. There is a need for budget impact analysis of Ticagrelor comparing with Clopidogrel in developing countries like India.
Source: CVD Prevention and Control - Category: Cardiology Authors: Tags: Poster Abstract Source Type: research